psychedelics

First subject dosed in psilocybin trial for rare headache disorder

The first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial for short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare disorder. The UK company says that SUNHA is a debilitating condition that is estimated to affect 40,000 patients in US and Europe. It is characterised by short, extremely …

First subject dosed in psilocybin trial for rare headache disorder Read More »

Beckley Psytech raises $80m for psychedelic meds development

UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical development of its psilocybin-based therapies. The Oxford-based company had originally hoped to raise $50 million from the series B, and the scale of the financing is further evidence that repurposing …

Beckley Psytech raises $80m for psychedelic meds development Read More »

MDMA on track for 2023 approval as PTSD therapy, says developer

A medicine based on MDMA – the active ingredient in recreational drug ecstasy – is on the cusp of FDA approval as a treatment for post-traumatic stress disorder (PTSD), according to the organisation developing it.  The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) is leading the development of MDMA and has just reported top-line results …

MDMA on track for 2023 approval as PTSD therapy, says developer Read More »

Magic mushroom compound matches antidepressant in clinical trial

The active compound in magic mushrooms – psilocybin – seems to be at least as effective as a commercially-available antidepressant in a phase 2 trial, and may work more quickly.  Researchers at Imperial College London’s Centre for Psychedelic Research also say that psilocybin may have a stronger effect and was more likely to help patients …

Magic mushroom compound matches antidepressant in clinical trial Read More »

VC fund dedicated to psychedelic meds launches in UK

In the last few years, biopharma companies focusing on psychedelic medicines have been springing up like mushrooms – magic or otherwise – and venture capital money is starting to follow. Today sees the launch of the first investment fund in the UK devoted to psychedelic healthcare, with plans to invest in “revolutionary mind-altering medicines to …

VC fund dedicated to psychedelic meds launches in UK Read More »